Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma

Table 6 Multivariate analysis for predictors of survival

Variable	Reference	HR	95%CI for HR	P value
Hepatitis B	Non-viral	0.900	0.674-1.200	0.472
Hepatitis C	Non-viral	1.086	0.841-1.401	0.527
Age at presentation	Years	1.009	1.000-1.018	0.062
Non-cirrhotic	Child Pugh C	0.267	0.165-0.433	< 0.001
Child Pugh A	Child Pugh C	0.403	0.287-0.566	< 0.001
Child Pugh B	Child Pugh C	0.705	0.501-0.992	0.045
Gender	Male	0.978	0.748-1.280	0.874
MELD	MELD score	1.016	0.999-1.033	0.072
Resection	Yes	2.212	1.434-3.413	< 0.001
Dominant lesion < 1 cm	Dominant lesion > 5 cm	0.375	0.156-0.898	0.028
Dominant lesion 1-3 cm	Dominant lesion > 5 cm	0.527	0.394-0.704	< 0.001
Dominant lesion 3-5 cm	Dominant lesion > 5 cm	0.740	0.550-0.995	0.046
Sorafenib	Yes	1.118	0.688-1.817	0.652
TACE	Yes	1.371	0.938-2.004	0.103
Transplant	Yes	8.486	5.185-13.889	< 0.001
Tumor extent < 50%	Tumor extent > 50%	0.690	0.476-1.000	0.050
Vascular invasion	Yes	0.555	0.393-0.784	0.001

MELD: Model for end stage liver disease; TACE: Trans arterial chemo embolisation.